Haiping He1,2,3,4, Yulin Cen1,2,3,4, Ping Wang5, Xu Zeng1,6, Shan Zeng1,2,3,4, Xinlong Li1,7, Xiaofei Lu8, Chuanhong Zhong1,2,3,4, Yang Ming1,2,3,4, Ligang Chen9,10,11,12, Lilei Peng13,14,15,16. 1. Department of Neurosurgery, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, People's Republic of China. 2. Sichuan Clinical Research Center of Neurosurgery, Luzhou, 646000, People's Republic of China. 3. Academician (Expert) Workstation of Sichuan Province, Luzhou, 646000, People's Republic of China. 4. Neurological Diseases and Brain Function Laboratory, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, People's Republic of China. 5. Department of Psychiatry, Luzhou People's Hospital, Luzhou, 646000, People's Republic of China. 6. Department of Neurosurgery, Zigong Second People's Hospital, Zigong, 643000, People's Republic of China. 7. Department of Neurosurgery, People's Hospital of Leshan, Leshan, 614000, People's Republic of China. 8. Department of Radiology, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, People's Republic of China. 9. Department of Neurosurgery, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, People's Republic of China. ligangchen_lgc@163.com. 10. Sichuan Clinical Research Center of Neurosurgery, Luzhou, 646000, People's Republic of China. ligangchen_lgc@163.com. 11. Academician (Expert) Workstation of Sichuan Province, Luzhou, 646000, People's Republic of China. ligangchen_lgc@163.com. 12. Neurological Diseases and Brain Function Laboratory, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, People's Republic of China. ligangchen_lgc@163.com. 13. Department of Neurosurgery, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, People's Republic of China. lilei.peng@swmu.edu.cn. 14. Sichuan Clinical Research Center of Neurosurgery, Luzhou, 646000, People's Republic of China. lilei.peng@swmu.edu.cn. 15. Academician (Expert) Workstation of Sichuan Province, Luzhou, 646000, People's Republic of China. lilei.peng@swmu.edu.cn. 16. Neurological Diseases and Brain Function Laboratory, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, People's Republic of China. lilei.peng@swmu.edu.cn.
Abstract
PURPOSE: Tumor immunotherapy has the advantages of high specificity, minimal damage to the patient's body, and a long-lasting anti-tumor effect. However, due to the existence of immune escape phenomenon, the effect of anti-tumor immunotherapy is still poor. Therefore, a cancer vaccine that reverses tumor-associated immunosuppression is a very promising approach for research and treatment. METHODS: Vaccines were prepared using autologous and allogeneic tumor cells and their lysates to syngeneic tumor cell lysates as immunogens. The glioma cell proliferation, apoptosis and the secretion level of MCP-2, IFN-γ were detected to evaluate the efficacy of this treatment against glioma in vitro. In addition, a rat glioma model was established to investigate the anti-tumor effect in vivo, and evaluated its efficacy by observing the changes of CD4 + T cells, CD8 + T cells, NK cells, and the level of IL-2 and IL-10 in peripheral blood before and after treatment. RESULTS: The C6 + 9L glioma cell lysate vaccine (C6 + 9L-CL) not only inhibited the proliferation of glioma cells and promoted their apoptosis in vitro, but also significantly inhibited the tumor growth in vivo and improved the survival time of rats. In addition, the C6 + 9L-CL vaccine enhanced the anti-tumor immune response by promoting the secretion of T cell chemokines MCP-2, IFN-γ and IL-2, and by stimulating the proliferation of T cells and NK cells in peripheral blood and glioma tissues. CONCLUSION: Our findings demonstrate the inhibitory effect of molecular mimic vaccines on glioma and provided a theoretical basis for molecular mimic hybrid vaccines as a potential therapeutic approach.
PURPOSE: Tumor immunotherapy has the advantages of high specificity, minimal damage to the patient's body, and a long-lasting anti-tumor effect. However, due to the existence of immune escape phenomenon, the effect of anti-tumor immunotherapy is still poor. Therefore, a cancer vaccine that reverses tumor-associated immunosuppression is a very promising approach for research and treatment. METHODS: Vaccines were prepared using autologous and allogeneic tumor cells and their lysates to syngeneic tumor cell lysates as immunogens. The glioma cell proliferation, apoptosis and the secretion level of MCP-2, IFN-γ were detected to evaluate the efficacy of this treatment against glioma in vitro. In addition, a rat glioma model was established to investigate the anti-tumor effect in vivo, and evaluated its efficacy by observing the changes of CD4 + T cells, CD8 + T cells, NK cells, and the level of IL-2 and IL-10 in peripheral blood before and after treatment. RESULTS: The C6 + 9L glioma cell lysate vaccine (C6 + 9L-CL) not only inhibited the proliferation of glioma cells and promoted their apoptosis in vitro, but also significantly inhibited the tumor growth in vivo and improved the survival time of rats. In addition, the C6 + 9L-CL vaccine enhanced the anti-tumor immune response by promoting the secretion of T cell chemokines MCP-2, IFN-γ and IL-2, and by stimulating the proliferation of T cells and NK cells in peripheral blood and glioma tissues. CONCLUSION: Our findings demonstrate the inhibitory effect of molecular mimic vaccines on glioma and provided a theoretical basis for molecular mimic hybrid vaccines as a potential therapeutic approach.
Authors: Julie R Brahmer; Scott S Tykodi; Laura Q M Chow; Wen-Jen Hwu; Suzanne L Topalian; Patrick Hwu; Charles G Drake; Luis H Camacho; John Kauh; Kunle Odunsi; Henry C Pitot; Omid Hamid; Shailender Bhatia; Renato Martins; Keith Eaton; Shuming Chen; Theresa M Salay; Suresh Alaparthy; Joseph F Grosso; Alan J Korman; Susan M Parker; Shruti Agrawal; Stacie M Goldberg; Drew M Pardoll; Ashok Gupta; Jon M Wigginton Journal: N Engl J Med Date: 2012-06-02 Impact factor: 91.245
Authors: Christine E Brown; Darya Alizadeh; Renate Starr; Lihong Weng; Jamie R Wagner; Araceli Naranjo; Julie R Ostberg; M Suzette Blanchard; Julie Kilpatrick; Jennifer Simpson; Anita Kurien; Saul J Priceman; Xiuli Wang; Todd L Harshbarger; Massimo D'Apuzzo; Julie A Ressler; Michael C Jensen; Michael E Barish; Mike Chen; Jana Portnow; Stephen J Forman; Behnam Badie Journal: N Engl J Med Date: 2016-12-29 Impact factor: 91.245
Authors: Sariah J Allen; Kevin R Mott; Aziz A Chentoufi; Lbachir BenMohamed; Steven L Wechsler; Christie M Ballantyne; Homayon Ghiasi Journal: J Virol Date: 2011-07-20 Impact factor: 5.103